1. Introduction {#sec0005}
===============

Prostate cancer (PCa) is the second most common cancer in men worldwide and the sixth most common cause of death [@bib0005]. There is a large degree of variation worldwide in both incidence and mortality because of differences in genetic background, lifestyle, the availability of screening programmes, and treatments.

Men with germline mutations in breast cancer 1, early onset (*BRCA1*) or breast cancer 2, early onset (*BRCA2*) genes have an increased risk of PCa. The relative risk of PCa by ≤65 yr is estimated at 1.8-fold to 4.5-fold for *BRCA1* carriers [@bib0010; @bib0015] and at 2.5-fold to 8.6-fold for *BRCA2* carriers [@bib0020; @bib0025; @bib0030]. A number of retrospective studies consistently report that *BRCA2* carriers present at a younger age with aggressive disease, higher rates of lymph node involvement, distant metastasis at diagnosis, and a higher mortality rate compared with noncarriers [@bib0035; @bib0040; @bib0045; @bib0050; @bib0055; @bib0060]. While there is debate about whether there is an increased risk of PCa for *BRCA1* carriers, there is increasing evidence that these men also present with more aggressive disease [@bib0035; @bib0045; @bib0065]. In addition, *BRCA2* mutation status has been confirmed as an independent prognostic factor for poorer outcome [@bib0035]. Therefore, targeted screening of *BRCA1/2* carriers for earlier detection may be beneficial.

The prostate-specific antigen (PSA) test is the most effective PCa biomarker currently available; however, its limitations are well documented. Expert groups have concluded that data from existing clinical trials---notably the Prostate, Lung, Colorectal and Ovary screening study (PLCO) [@bib0070] and the European Randomised Study of Screening for Prostate Cancer (ERSPC) [@bib0075]---are insufficient to recommend routine general population PSA screening. The main scientific challenge is to differentiate between men who will benefit from screening and men who will not, reducing overdiagnosis and overtreatment while maintaining benefits (ie, lower mortality).

There is no international consensus on targeting screening at men at higher risk. There have been a limited number of studies of screening in men with a family history of PCa [@bib0080; @bib0085; @bib0090]. Most of the studies support the use of targeted screening; however, methodological differences make it difficult to draw conclusions from these data [@bib0080; @bib0085; @bib0095; @bib0100; @bib0105; @bib0110; @bib0115; @bib0120; @bib0125; @bib0130]. The IMPACT study (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in *BRCA1/2* mutation carriers and controls; [www.impact-study.co.uk](http://www.impact-study.co.uk/){#intr0005}) is an international, multicentre study evaluating the role of targeted PSA screening in men with *BRCA1/2* mutations. The aims of IMPACT are to evaluate the utility of PSA screening, to determine PCa incidence, to assess the positive predictive value (PPV) of biopsy using a PSA threshold of 3.0 ng/ml, to determine biopsy rates, and to evaluate the characteristics of the tumours to establish whether PSA screening detects clinically significant disease in this population compared with the control group. This analysis reports the results of the first screening round for all men enrolled in IMPACT from October 2005 to February 2013.

2. Materials and methods {#sec0010}
========================

The IMPACT study design and methods have previously been reported elsewhere [@bib0135; @bib0140] and are summarised below ([Fig. 1](#fig0005){ref-type="fig"}). The protocol was approved by the West-Midlands Research and Ethics Committee in the United Kingdom (reference 05/MRE07/25) and subsequently by each participating institution\'s local committee. All participants provide written consent, and interim analyses are presented to the Independent Data and Safety Monitoring Committee biannually.

The target sample is 500 *BRCA1* mutation carriers and 350 *BRCA2* mutation carriers and a control group of 850 men who tested negative for a pathogenic *BRCA* mutation in their family. IMPACT has been powered to detect a twofold increased risk over 5 yr of screening, with 80% power at *p* \< 0.01.

We recruited men aged 40--69 from families with a *BRCA* mutation between October 2005 and February 2013. Men were recruited from cancer genetics clinics from families with known pathogenic *BRCA1* or *BRCA2* mutations. Men from these families could enter the study if they had tested positive or negative for the mutation, or if they were at 50% risk of inheriting a mutation but had not yet undergone testing. Men in the latter group were tested within the study to be allocated to the appropriate group for analysis, but this result was not fed back to participants. Men were excluded if they were known to have PCa or if they had a prior cancer diagnosis with a prognosis of \<5 yr. In the Dutch cohort, men were also excluded if they had prior PSA screening.

Participants underwent PSA testing at enrolment, and if their PSA value was \>3.0 ng/ml, a 10-core transrectal ultrasound--guided prostate biopsy was recommended. PSA quality assurance was measured on a concurrent serum sample. All available samples were tested using the ProStatus PSA Free/Total DELFIA assay at SUS (Malmö, Sweden). In addition, in men undergoing biopsy, serum samples were tested for microseminoprotein (MSP) and four kallikrein markers (free PSA, intact PSA, total PSA, and human kallikrein-related peptidase 2 \[hK2\]). The methods have been described previously [@bib0145; @bib0150]. The results from the four kallikrein markers were combined to create a risk score (Rotterdam score) using a previously described model [@bib0150].

Participants with PSA ≤3.0 ng/ml will undergo annual PSA screening for ≥5 yr, except participants in the Dutch cohort, who are screened biennially (because of the constraints of the ministerial approval). Participants with PSA \>3.0 ng/ml and a negative biopsy will undergo annual PSA testing, repeating the biopsy if PSA increases by \>50%. All participants will be followed up for ≥5 yr to evaluate the cancer incidence and PCa-specific mortality and morbidity [@bib0135; @bib0140].

The local histopathologist at each centre reported the biopsy results to guide treatment in accordance with local guidelines. The Gleason score, clinical stage, and classification of disease into low, intermediate, or high risk of metastasis [@bib0155] were reported for each case. Central pathology review was performed by the study pathologist (C.S.F.) to ensure consistency and standardisation. Prostate core biopsies were assessed in accordance with International Society of Urological Pathology guidelines [@bib0160] (described previously [@bib0050; @bib0165]). Whenever high-grade prostate intraepithelial neoplasia (HG PIN) or atypical small acinar proliferation (ASAP) was detected, the biopsy was repeated within 3--6 mo.

2.1. Statistical analysis {#sec0015}
-------------------------

Statistical analysis was undertaken using SPSS v.21 and Stata 12.0. The Fisher exact test was used to compare the number of PCa cases detected among groups and differences among disease types. The PPV of the biopsy using PSA \>3.0 ng/ml in the different groups was compared using the chi-square test for independence. To compare the mean ages of men with high PSA levels, *t* tests were used; *p* \< 0.05 was considered statistically significant. The Wald test was used to test the association between evidence of PCa at biopsy and the Rotterdam score, and the Spearman correlation was used to determine the relationship between PSA measurements taken in the clinical and laboratory settings.

3. Results {#sec0020}
==========

3.1. Study population {#sec0025}
---------------------

A total of 2481 participants from 62 centres in 20 countries were recruited over 90 mo (Supplemental Table 1); there were 791 *BRCA1* carriers and 531 *BRCA1* controls, as well as 731 *BRCA2* carriers and 428 *BRCA2* controls) ([Fig. 2](#fig0010){ref-type="fig"}).

The majority of participants were white (95%) and highly educated (measured using self-reported qualifications), and the mean age at enrolment was 54 yr ([Table 1](#tbl0005){ref-type="table"}). Twenty-one percent of the men reported urinary symptoms, and 37% had previously had at least one PSA test. No statistically significant differences were observed among groups; 27% reported a family history of PCa in at least one blood relative.

3.2. Prostate cancer detection rates at initial screening and positive predictive value of biopsy {#sec0030}
-------------------------------------------------------------------------------------------------

Of the 2481 men, 199 (8.0%) had PSA \>3.0 ng/ml (range: 3.0--27.0; median: 4.3) and were referred to a urologist to discuss prostate biopsy ([Fig. 2](#fig0010){ref-type="fig"}). Of these men, 162 (81.4%) underwent biopsy. Biopsies were declined because of concurrent health conditions (*n* = 7), the urologist\'s choosing to repeat the PSA test prior to biopsy resulting in a reading ≤3.0 ng/ml (*n* = 17), men changing their minds (*n* = 8), or reason missing (*n* = 5). Fifty-nine of 162 biopsies (36.4%) contained cancer. There was no significant difference in cancer detection rates between men who had or had not undergone PSA screening prior to study entry. No significant differences were seen with the Dutch cohort, in which men with prior PSA screening were excluded. Other than in the Dutch cohort, the prior screening levels were similar in all countries.

The PCa detection rate was 2.4% (59 of 2481 men) ([Table 2](#tbl0010){ref-type="table"}). The detection rate for *BRCA1* carriers was 2.3% (18 of 791); it was 1.9% (10 of 531) for *BRCA1* controls, 3.3% (24 of 731) for *BRCA2* carriers, and 1.6% (7 of 428) for *BRCA2* controls, with no significant difference among groups. The number of cores taken at biopsy ranged from 6 to 20; however, there were no differences in the median or mean number of cores taken among groups ([Table 2](#tbl0010){ref-type="table"}). Four men had either ASAP or HG PIN (all mutation carriers) ([Table 2](#tbl0010){ref-type="table"}). Two men underwent repeat biopsy with no cancers detected. Taking potential geographical variation in cancer incidence into consideration, the data were analysed by region (North America; Australia; Asia; and Western, Central, and Southern Europe), and no statistically significant differences were observed.

The PPV of biopsy using a PSA threshold of 3.0 ng/ml (ie, the number of cancers detected divided by the number of biopsies performed) was 36% (59 of 162) ([Table 2](#tbl0010){ref-type="table"}). Broken down by genetic status, the PPV in *BRCA1* carriers was 37.5% (18 of 48); in *BRCA1* controls, 23.3% (10 of 43); in *BRCA2* carriers, 48.0% (24 of 50); and in *BRCA2* controls, 33.3% (7 of 21). There was no statistically significant difference among groups (Pearson chi-square test for *BRCA1, p* = 0.14; for *BRCA*2, *p* = 0.26).

There was no significant difference between either mean age at PCa diagnosis or PSA level among groups. Twelve men (20%) reported urinary symptoms prior to diagnosis, and 20 men (34%) had a PSA test prior to study entry (29% *BRCA2* carriers, 50% *BRCA2* controls; 44% *BRCA1* carriers, 33% *BRCA1* controls). There was no difference observed in levels of PSA screening prior to study entry among groups.

Using the NICE classification [@bib0155; @bib0170], intermediate- or high-risk tumours were diagnosed in 11 of 18 *BRCA1* carriers (61%) compared with 8 of 10 *BRCA1* controls (80%) and in 17 of 24 *BRCA2* carriers (71%) compared with 3 of 7 *BRCA2* controls (43%) ([Table 3](#tbl0015){ref-type="table"}). There was no significant difference observed between genetic status and disease risk status. The PPV of biopsy using a PSA threshold of 3.0 ng/ml for detecting intermediate- and high-risk PCa for *BRCA2* carriers and controls was 2.38% (17 of 714) and 0.71% (3 of 425), respectively; this difference is significant (Pearson chi-square, *p* = 0.04). No significant difference was observed in *BRCA1* carriers compared with controls (1.41% \[11 of 780\] compared with 1.33% \[8 of 524\]; Pearson chi-square test, *p* = 0.86). No cases had nodal involvement or metastatic disease at diagnosis.

3.3. Central analysis of prostate-specific antigen and the kallikrein panel {#sec0035}
---------------------------------------------------------------------------

There was a strong correlation between PSA values measured in the clinical and laboratory settings (Spearman *r* = 0.85). Serum samples of 57 (24 with PCa) of the 162 men who underwent a biopsy were analysed for MSP and four kallikrein markers ([Table 4](#tbl0020){ref-type="table"}).

We found no association between PCa at biopsy and total PSA or MSP ([Table 5](#tbl0025){ref-type="table"}). We compared the proportion of PCa in mutation carriers with controls and found no association between PCa at biopsy and mutation status. There was an association of PCa at biopsy and Rotterdam score (Wald test *p* = 0.024). The discrimination of the Rotterdam model was 0.70 (95% confidence interval \[CI\], 0.56--0.84). For the outcome of high-grade cancer, the Rotterdam score was the only statistically significant predictor (*p* = 0.009), with a discrimination of 0.86 (95% CI, 0.73--0.99).

For 1202 of 2481 participants with available blood samples, we found a strong correlation of total PSA between measurements taken in the clinical and laboratory settings (Spearman *r* = 0.95).

3.4. Serious adverse events {#sec0040}
---------------------------

Six study-related serious adverse events were reported, all occurring after biopsy. Complications occurred in 6 of 158 participants (3.8%), with five infections (3.2%) reported, two requiring hospitalisation. The sixth participant was hospitalised because of fainting after biopsy.

4. Discussion {#sec0045}
=============

In this paper we have presented the results of the first screening round of IMPACT, including the number and features of the PCa detected. With germline mutations in *BRCA1* and B*RCA2* being rare, the success of IMPACT has been in the formation of an international consortium of 62 centres with both clinical genetics and urologic collaboration. Enrolment was open until the required number of recruits was obtained in all four cohorts, exceeding the numbers required for statistical power in all groups.

Compliance with the protocol was high, with 162 men with PSA \>3.0 ng/ml (\>81%) proceeding to biopsy. This number compares favourably with the 86% in the ERSPC [@bib0175] and the 31.5% in the PLCO study [@bib0175; @bib0180; @bib0185]. In the PLCO study, with no strict protocol to guide intervention, 74% of men with an abnormal screening test underwent further diagnostic evaluation, and 64% underwent biopsy within 3 yr [@bib0185]. Thus, a similar increase in compliance may be anticipated in IMPACT at subsequent screening rounds. The potential utility of multiparametric magnetic resonance imaging (MRI) as a screening tool before biopsy has been the subject of recent debate [@bib0190]; however, the IMPACT protocol was designed prior to the use of MRI in this diagnostic capacity.

In total, 8% of the men had a positive PSA test (\>3.0 ng/ml), which is lower than the 16.2% (range: 11.1--22.3% among sites) reported in the ERSPC general population screening study [@bib0175]. However, the ERSPC recruited an older cohort of men (55--75 yr), with a mean age of 61 yr compared with 54 yr in IMPACT. It is known that PSA increases with age, so higher PSA levels would be expected. In addition, a number of ERSPC centres used a threshold of 4.0 ng/ml rather than 3.0 ng/ml to determine biopsy, so the two studies are not entirely directly comparable. These results indicate that overbiopsy is not a concern in this younger cohort.

There is controversy about the PSA level used to trigger biopsy, with no clear consensus. The results presented show that while not statistically significant, the PPV of biopsy using a PSA threshold of 3.0 ng/ml is higher for *BRCA2* carriers than for controls (48% vs 33%) and higher for *BRCA1* carriers than controls (41% vs 23%). For *BRCA2* carriers, this percentage is double the 24.1% reported in the ERSPC general population sample. This higher PPV observed in mutation carriers may be explained, at least in part, by the fact that the ERSPC screened older men. Also, given the younger age of the IMPACT cohort, the incidence of benign prostatic hypertrophy (BPH) may have been lower; the incidence of BPH increases with age, and BPH lowers the specificity of PSA screening [@bib0135; @bib0195; @bib0200]. These data suggest that lowering the PSA threshold for biopsy in *BRCA2* carriers could potentially detect early-stage disease, thus reducing the need for more toxic treatments and ultimately reducing PCa mortality. However, this lowering would need to be balanced against the risk of potentially life-threatening side-effects of biopsy [@bib0205; @bib0210].

In IMPACT, men will be offered a prostate biopsy at the end of the study (at the centres with the capacity), which may provide evidence for the optimal PSA threshold for detecting clinically significant PCa in this cohort of higher-risk men.

The observed differences in PPV may also reflect the higher incidence and grade of PCa previously reported, particularly in *BRCA2* carriers. The higher PPV in *BRCA2* carriers suggests that PSA may have a higher specificity in this high-risk setting. However, as the number of cancers is relatively small, subsequent PSA screening rounds are essential to confirm this hypothesis. Evaluation of the panel of four kallikrein markers in subsequent screening rounds may provide further insights into the panel\'s potential role in predicting biopsy outcome [@bib0150].

The ERSPC reported that 4.2% of men had a cancer diagnosis at the first screening round [@bib0215]. In IMPACT, the PCa detection rate was 2.4%, and two-thirds of the men in the cohort were previously unscreened. The younger age of the IMPACT sample is likely to explain this lower detection rate. More than two-thirds of the PCa detected in the *BRCA2* carriers were classified as intermediate -- or high -- risk, supporting retrospective reports of a more aggressive phenotype and poorer prognosis in this group [@bib0035; @bib0040; @bib0045; @bib0050; @bib0055; @bib0060]. Sixty-one percent of *BRCA1* carriers were classified as having intermediate- or high-risk disease. By comparison, in the ERSPC, only 27.8% of the PCa diagnosed in the screened cohort were Gleason score ≥7 [@bib0175]. Longer-term follow-up will determine whether there is a difference in metastatic events and mortality between carriers and controls. From the PLCO study, after 13 yr of follow-up, there is no evidence to support the idea that organised PSA screening reduces mortality compared with opportunistic screening [@bib0070]. In contrast, after a median of 11 yr of follow-up, the ERSPC reported a 21% reduction in PCa-specific mortality in the screened cohort [@bib0075]. It is important to note that in the PLCO, 56% of men in the control arm had PSA screening, compared with 15% in the ERSPC.

The higher incidence of clinically significant disease in the *BRCA2* mutation carriers, together with the significantly younger age of *BRCA2* carriers with PSA \>3.0 ng/ml, is an important observation in view of the younger age of this cohort compared with the ERSPC study. The only cancers detected in men \<50 yr were in *BRCA1* and *BRCA2* carriers. These data add to the increasing evidence that *BRCA1/2* carriers develop more aggressive disease, and at a younger age. Of note, the control groups also had a higher level of intermediate- or high-risk disease compared with the ERSPC. However, the number of cancers is relatively small, and with 19% of men declining biopsy, these data should be interpreted with caution.

The population incidence of PCa in each of the recruiting countries must be considered. The incidence in the majority of the countries is very similar, except in India and Malaysia [@bib0220]. Given the relatively low number of recruits from these regions, geographical variation is unlikely to have a major impact on the results. A limitation of IMPACT is that 95% of the men were white. Thus, the results cannot be generalised to all ethnic groups known to have a higher risk of PCa and a more aggressive phenotype (eg, black). A second limitation is that 37% of the cohort had previously had a PSA test. This fact could potentially bias the study to either having men with a lower PSA or having men with higher PSAs due to noncancerous causes. However, no difference in screening levels was observed among those men with and without cancer. A further limitation is that the control group was recruited from families known to have *BRCA* mutations. It is possible that this group of men has a different PCa risk profile than the general population.

5. Conclusions {#sec0050}
==============

The first screening round of IMPACT demonstrates that targeted screening for PCa in men with a genetic predisposition detects clinically significant disease. Using a PSA threshold of 3 ng/ml results in a low biopsy rate (8.0%) and a high PPV, particularly in *BRCA2* carriers, for the detection of intermediate- and high-risk disease. Although the observed differences in PCa detection rates between carriers and controls was not statistically significant, the trend is clear. With larger numbers of PCa in the follow-up phase (5 yr), these differences, if sustained, are likely to be significant.

Future screening rounds will determine the optimal frequency of PSA testing, determine the utility of PSA screening in *BRCA1* carriers, and provide further data on the value of annual screening in *BRCA2* carriers.

A previously published statistical model based on four kallikrein markers was able to predict biopsy outcome in participants with PSA \>3 ng/ml with a discrimination of 0.86 for high-grade disease. Longer-term follow-up will be used to validate the role of the kallikrein panel in this population.

IMPACT is the first prospective study to demonstrate the use of germline genetic markers to identify men at higher risk of PCa, which has the potential to enable better risk stratification to inform targeted screening. These early results indicate that the tumours detected are more likely to need treatment based on national guidelines for management of more aggressive PCa. Therefore, our preliminary results support the use of PSA screening for *BRCA2* carriers. 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![Study design.\
ASAP = atypical small acinar proliferation; PIN = prostate intraepithelial neoplasia; PSA = prostate-specific antigen; QoL = quality-of-life.](gr1){#fig0005}

![Consort diagram for the first round of screening.\
*BRCA1* *=* breast cancer 1, early onset; *BRCA2* *=* breast cancer 2, early onset; PSA = prostate-specific antigen; PPV = positive predictive value.\
^\*^ Controls were men who had a negative predictive genetic test for the *BRCA* mutation in their family.](gr2){#fig0010}

###### 

Sociodemographic characteristics

                                               *BRCA1*+ (*n* = 791)   *BRCA1*− (*n* = 531)   *BRCA2*+ (*n* = 731)   *BRCA2*− (*n* = 428)   Total cohort
  -------------------------------------------- ---------------------- ---------------------- ---------------------- ---------------------- --------------
  Age group, yr, no. (%)                                                                                                                   
   40--49                                      264 (33)               148 (28)               298 (41)               118 (28)               828 (33)
   50--59                                      294 (37)               224 (42)               254 (35)               169 (40)               941 (38)
   60--69                                      233 (30)               159 (30)               179 (25)               141 (33)               712 (29)
  Qualifications, no. (%)                                                                                                                  
   No qualifications                           33 (4)                 13 (2)                 39 (5)                 24 (6)                 109 (4)
   School to 16                                105 (13)               59 (11)                116 (16)               43 (10)                323 (13)
   School to 18/college degree                 133 (17)               117 (22)               89 (12)                86 (20)                425 (17)
   Technical/vocational qualifications         191 (24)               134 (25)               143 (20)               81 (19)                549 (22)
   University graduate                         273 (35)               179 (34)               267 (37)               145 (34)               864 (35)
   Other                                       15 (2)                 16 (3)                 26 (4)                 17 (4)                 74 (3)
   Unknown                                     41 (5)                 13 (2)                 51 (7)                 32 (7)                 137 (6)
  Family history of prostate cancer, no. (%)                                                                                               
   Yes                                         177 (22)               142 (27)               234 (32)               129 (30)               682 (27)
   No                                          528 (67)               307 (58)               453 (62)               249 (58)               1537 (62)
   Unknown                                     86 (11)                82 (15)                44 (6)                 50 (12)                262 (11)
  Ethnicity, no. (%)                                                                                                                       
   Caucasian                                   750 (95)               514 (97)               695 (95)               410 (96)               2369 (95.5)
   East Asian                                  3 (0.4)                1 (0.2)                3 (0.4)                1 (0.2)                8 (0.3)
   North Asian                                 8 (1,0)                6 (1.1)                0                      2 (0.5)                16 (0.6)
   Caribbean                                   1 (0.1)                0                      0                      0                      1 (0.0)
   Aboriginal/Torres Strait Islander           1 (0.1)                0                      1 (0.1)                0                      2 (0.1)
   Mixed white and Caribbean                   5 (0.6)                2 (0.4)                2 (0.3)                1 (0.2)                10 (0.4)
   Mixed white and Asian                       3 (0.4)                0                      0                      0                      3 (0.1)
   Any other Asian background                  0                      0                      1 (0.1)                0                      1 (0.04)
   Any other mixed background                  3 (0.4)                1 (0.2)                1 (0.1)                0                      5 (0.2)
   Any other                                   15 (2)                 7 (1)                  22 (3)                 5 (1)                  49 (2)
   Not given                                   2 (0.3)                0                      6 (0.8)                9 (2)                  17 (0.7)

*BRCA1* *=* breast cancer 1, early onset; *BRCA2* = breast cancer 2, early onset.

###### 

Summary of outcomes for men with prostate-specific antigen level \>3.0 ng/ml

                                            *BRCA1*+ (*n* = 791)   *BRCA1*− (*n* = 531)   *BRCA2*+ (*n* = 731)   *BRCA2*− (*n* = 428)   Total cohort (*n* = 2481)
  ----------------------------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------------
  Men PSA \>3.0 ng/ml, no.                  60                     52                     59                     28                     199
  Mean age, yr                              60.1                   59.8                   58.1                   62.2                   59.7
  Biopsy rate, %                            7.6                    9.8                    8.1                    6.5                    8.0
  Biopsies performed, no.                   48                     43                     50                     21                     162
   Biopsy--benign, no.                      27                     33                     25                     14                     99
   Biopsy--cancer, no.                      18                     10                     24                     7                      59
   Biopsy--ASAP/HG PIN, no.                 3                      0                      1                      0                      4
  No biopsy, no.                            12                     9                      9                      7                      37
  PPV of biopsy, %                          37.5                   23.3                   48.0                   33.3                   36.4
  Biopsy cores, no., median; mean (range)   10; 9.4 (6--13)        11; 10.3 (6--20)       10; 10.1 (5--12)       10; 10.1 (6--13)       10; 9.9 (5--20)

*BRCA1* *=* breast cancer 1, early onset; *BRCA2* *=* breast cancer 2, early onset; PSA = prostate-specific antigen; ASAP/HG PIN = atypical small acinar proliferation/high-grade prostate intraepithelial neoplasia; PPV = positive predictive value.

###### 

Clinical features of the prostate cancers at diagnosis

  Patient   Status     Age, yr   Disease risk classification   PSA test prior to study entry   PSA, ng/ml   Gleason score   Clinical stage                          Treatment                               Family history of prostate cancer   Urinary symptoms
  --------- ---------- --------- ----------------------------- ------------------------------- ------------ --------------- --------------------------------------- --------------------------------------- ----------------------------------- ------------------
  1         *BRCA1*+   55        High                          Yes                             5.9          4 + 4           pT2c                                    Prostatectomy                           No                                  No
  2         *BRCA1*+   69        High                          Yes                             6.3          3 + 3           pT3b                                    Prostatectomy                           No                                  Yes
  3         *BRCA1*+   60        High                          Yes                             3.3          3 + 3           pT3a                                    Prostatectomy                           Yes                                 No
  4         *BRCA1*+   59        High                          No                              3.8          3 + 5           T3a                                     [\*](#tblfn0005){ref-type="table-fn"}   Yes                                 No
  5         *BRCA1*+   61        Intermediate                  No                              9.7          3 + 4           T1c                                     Prostatectomy                           No                                  No
  6         *BRCA1*+   61        Intermediate                  Yes                             4.5          3 + 4           pT2c                                    Prostatectomy                           Yes                                 No
  7         *BRCA1*+   69        Intermediate                  Yes                             7.4          3 + 3           T2b                                     Radiotherapy                            Yes                                 Yes
  8         *BRCA1*+   53        Intermediate                  No                              3.9          3 + 3           T2                                      Prostatectomy                           No                                  No
  9         *BRCA1*+   63        Intermediate                  No                              4.2          3 + 3           pT2c                                    Prostatectomy                           Yes                                 No
  10        *BRCA1*+   49        Intermediate                  Yes                             3.8          3 + 3           pT2c                                    Prostatectomy                           No                                  No
  11        *BRCA1*+   45        Intermediate                  No                              3.2          3 + 4           T2b                                     Prostatectomy                           Yes                                 No
  12        *BRCA1*+   61        Low                           Yes                             4.1          3 + 3           T1c                                     Active surveillance                     No                                  No
  13        *BRCA1*+   56        Low                           No                              5.3          3 + 3           pT2a                                    Prostatectomy                           Yes                                 No
  14        *BRCA1*+   63        Low                           Yes                             3.4          3 + 3           pT2a                                    Prostatectomy                           No                                  Yes
  15        *BRCA1*+   57        Low                           No                              3.7          3 + 3           T1c                                     Prostatectomy                           No                                  No
  16        *BRCA1*+   64        Low                           No                              5            3 + 3           T1c                                     Active surveillance                     No                                  No
  17        *BRCA1*+   64        Low                           No                              6.2          3 + 3           T1c                                     Active surveillance                     No                                  No
  18        *BRCA1*+   48        Low                           No                              5.3          3 + 3           [\*](#tblfn0005){ref-type="table-fn"}   [\*](#tblfn0005){ref-type="table-fn"}   No                                  No
  19        *BRCA1*−   61        High                          Yes                             7.7          4 + 3           pT3a                                    Prostatectomy                           No                                  No
  20        *BRCA1*−   62        High                          Yes                             3.1          3 + 4           pT3a                                    Prostatectomy                           Yes                                 Yes
  21        *BRCA1*−   62        Intermediate                  No                              3.3          3 + 3           pT2c                                    Prostatectomy                           No                                  No
  22        *BRCA1*−   61        Intermediate                  No                              4.8          3 + 3           T2c                                     Prostatectomy                           No                                  Yes
  23        *BRCA1*−   66        Intermediate                  Yes                             5.5          4 + 3           T1c                                     Radiotherapy                            Yes                                 No
  24        *BRCA1*−   57        Intermediate                  No                              4.5          3 + 4           T2c                                     Prostatectomy                           Yes                                 Yes
  25        *BRCA1*−   55        Intermediate                  No                              5.2          3 + 4           pT2                                     Prostatectomy                           No                                  No
  26        *BRCA1*−   65        Intermediate                  No                              4.7          3 + 3           pT2c                                    Prostatectomy                           No                                  No
  27        *BRCA1*−   59        Low                           No                              4.3          3 + 3           T1c                                     Active surveillance                     Yes                                 No
  28        *BRCA1*−   62        Low                           Unknown                         9.9          3 + 3           T1c                                     Prostatectomy                           No                                  No
  29        *BRCA2*+   66        High                          Yes                             5            3 + 4/4 + 3     pT3a                                    Prostatectomy                           No                                  No
  30        *BRCA2*+   51        High                          No                              27           4 + 3           pT3a                                    Prostatectomy                           Yes                                 No
  31        *BRCA2*+   66        High                          No                              24           4 + 4           T4                                      Radiotherapy                            No                                  No
  32        *BRCA2*+   66        High                          Yes                             11           4 + 5           T3a                                     Prostatectomy                           No                                  No
  33        *BRCA2*+   61        High                          No                              6.3          4 + 5           T1c                                     Prostatectomy                           No                                  No
  34        *BRCA2*+   67        High                          No                              12.8         3 + 3           T3a                                     Brachytherapy                           No                                  No
  35        *BRCA2*+   62        High                          Yes                             8.2          3 + 4           pT3a                                    Prostatectomy                           Yes                                 Yes
  36        *BRCA2*+   49        Intermediate                  Unknown                         4.9          3 + 4           T2c                                     Prostatectomy                           No                                  No
  37        *BRCA2*+   68        Intermediate                  Yes                             5.3          3 + 4           T2b                                     Radiotherapy                            No                                  No
  38        *BRCA2*+   54        Intermediate                  No                              3.1          3 + 3           pT2c                                    Prostatectomy                           No                                  No
  39        *BRCA2*+   56        Intermediate                  No                              5            3 + 4           pT2c                                    Prostatectomy                           Yes                                 No
  40        *BRCA2*+   59        Intermediate                  Yes                             3            3 + 4           T2c                                     Prostatectomy                           Yes                                 No
  41        *BRCA2*+   58        Intermediate                  No                              5.1          4 + 3           pT2c                                    Prostatectomy                           No                                  No
  42        *BRCA2*+   41        Intermediate                  No                              3.5          3 + 4           pT2c                                    Prostatectomy                           Yes                                 Yes
  43        *BRCA2*+   65        Intermediate                  No                              4.7          3 + 4           T1c                                     Radiotherapy                            No                                  No
  44        *BRCA2*+   53        Intermediate                  No                              3.6          3 + 3           T2c                                     Prostatectomy                           No                                  No
  45        *BRCA2*+   63        Intermediate                  No                              3.5          3 + 3           pT2c                                    Prostatectomy                           Yes                                 Yes
  46        *BRCA2*+   67        Low                           No                              4.8          3 + 3           T2a                                     Active surveillance                     No                                  No
  47        *BRCA2*+   55        Low                           No                              4.5          3 + 3           T1c                                     Active surveillance                     Yes                                 Yes
  48        *BRCA2*+   61        Low                                                           3.6          3 + 3           T1c                                     Brachytherapy                           No                                  Yes
  49        *BRCA2*+   57        Low                           No                              4.9          3 + 3           T1c                                     Active surveillance                     No                                  Yes
  50        *BRCA2*+   45        Low                           No                              4.7          3 + 3           T1c                                     Active surveillance                     No                                  No
  51        *BRCA2*+   61        Low                           No                              4.1          3 + 3           T1c                                     Active surveillance                     No                                  No
  52        *BRCA2*+   54        Low                           Yes                             3.3          3 + 3           T1c                                     Active surveillance                     Yes                                 No
  53        *BRCA2*−   69        High                          No                              14.3         4 + 3           T3                                      Radiotherapy                            No                                  No
  54        *BRCA2*−   62        Intermediate                  No                              4.8          3 + 4           pT2c                                    Prostatectomy                           No                                  No
  55        *BRCA2*−   65        Intermediate                  Yes                             4.2          3 + 3           T1c                                     Active surveillance                     No                                  No
  56        *BRCA2*−   60        Low                           No                              5.5          3 + 3           T1c                                     Active surveillance                     No                                  No
  57        *BRCA2*−   68        Low                           Yes                             3.3          3 + 3           T1c                                     Active surveillance                     No                                  No
  58        *BRCA2*−   66        Low                           Yes                             6.7          3 + 3           T2a                                     Prostatectomy                           No                                  No
  59        *BRCA2*−   53        Low                           Unknown                         3.4          3 + 3           T2b                                     Prostatectomy                           No                                  No

*BRCA1* *=* breast cancer 1, early onset; *BRCA2* *=* breast cancer 2, early onset; PSA = prostate-specific antigen.

Data pending.

###### 

Patient characteristics for kallikrein analysis[\*](#tblfn0010){ref-type="table-fn"}

  Characteristics                                      No cancer (*n* = 33)   Cancer (*n* = 24)
  ---------------------------------------------------- ---------------------- ----------------------
  *BRCA1* tested, no. (%)                              18 (55)                11 (46)
  *BRCA1*+, no. (%)                                    10 (56)                10 (91)
  *BRCA2* tested, no. (%)                              15 (45)                13 (54)
  *BRCA2*+, no. (%)                                    12 (80)                10 (77)
  Age at study entry, yr, median (quartiles)           59 (55, 64)            61 (57, 66)
  Specific site total PSA, ng/ml, median (quartiles)   4.2 (3.4, 5.0)         4.4 (3.7, 5.2)
  Central site total PSA, ng/ml, median (quartiles)    3.9 (3.4, 5.1)         4.2 (3.3, 5.4)
  Free PSA, ng/ml, median (quartiles)                  0.93 (0.73, 1.19)      0.83 (0.53, 0.96)
  Intact PSA, ng/ml, median (quartiles)                0.53 (0.42, 0.69)      0.47 (0.31, 0.67)
  hK2, ng/ml, median (quartiles)                       0.051 (0.038, 0.076)   0.062 (0.036, 0.083)
  MSP, ng/ml, median (quartiles)                       19 (11, 26)            18 (11, 24)
  Rotterdam score                                      0.235 (0.162, 0.310)   0.327 (0.243, 0.373)
  Gleason total score, no. (%)                                                
   6                                                                          17 (71)
   7                                                                          7 (29)
  Clinical T stage, no. (%)                                                   
   T1C                                                                        8 (33)
   T2                                                                         2 (8.3)
   T2A                                                                        1 (4.2)
   T2B                                                                        2 (8.3)
   T2C                                                                        3 (13)
   T3                                                                         1 (4.2)
   Unknown                                                                    7 (29)

*BRCA1* *=* breast cancer 1, early onset; *BRCA2* *=* breast cancer 2, early onset; PSA = prostate-specific antigen; hK2 = human kallikrein-related peptidase 2; MSP = microseminoprotein.

Data are frequency (percentage) or median (quartiles).

###### 

Univariate logistic regression for the outcomes of evidence of prostate cancer at biopsy and evidence of high-grade prostate cancer at biopsy[\*](#tblfn0015){ref-type="table-fn"}

  Predictor                                                           Odds ratio   95% CI         *p* value
  ------------------------------------------------------------------- ------------ -------------- -----------
  Total PSA, ng/ml (*n* = 57)                                                                     
   Cancer                                                             1.02         0.75--1.37     0.9
   High-grade cancer                                                  1.49         1.00--2.23     0.051
  Rotterdam score (*n* = 57)[\*\*](#tblfn0020){ref-type="table-fn"}                               
   Cancer                                                             2.30         1.25--4.22     0.007
   High-grade cancer                                                  3.87         1.42--10.60    0.008
  MSP, ng/ml (*n* = 57)                                                                           
   Cancer                                                             1.00         0.95--1.04     0.8
   High-grade cancer                                                  0.95         0.86--1.03     0.2
  *BRCA1* status (*n* = 29)^+^                                                                    
   Cancer                                                             8.00         0.76--389.69   0.10
   High-grade cancer[†](#tblfn0025){ref-type="table-fn"}                                          0.5
  *BRCA2* status (*n* = 28)^+^                                                                    
   Cancer                                                             0.83         0.09--7.73     1
   High-grade cancer                                                  1.47         0.11--83.27    1
  Mutation status (*n* = 57)^+^                                                                   
   Cancer                                                             2.50         0.60--12.35    0.2
   High-grade cancer                                                  2.33         0.24--114.86   0.7

CI = confidence interval; *BRCA1* *=* breast cancer 1, early onset; *BRCA2* *=* breast cancer 2, early onset; MSP = microseminoprotein; PSA = prostate-specific antigen.

Subset of 57 men biopsied for whom an adequate serum sample was available.

The odds ratio for the Rotterdam score corresponds to a 0.1-unit increase on a 0--1 probability scale.

^+^ The 95% CI and *p* values are calculated using the Fisher exact test.

The odds ratio and 95% CI are not estimable because of zero events in the *BCRA1*-negative group. The *p* value is calculated from the chi-square test.

[^1]: See online Supplement.
